[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"motor-recovery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:motor-recovery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,65,79,93,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100518324","tacs-for-sensory-motor-recovery-after-stroke-100518324",false,"NCT06029062","tACS for Sensory Motor Recovery After Stroke","tACS Brain Neuromodulation for Sensory and Motor Recovery After Neurological Impairments","Inclusion\u002Fexclusion criteria for stroke subjects\n\nInclusion criteria:\n\n1. Age between 18\\~75 years old\n2. ≥ 6 months post stroke, medically stable;\n3. Unilateral, single stroke (no restriction on type (ischemic or hemorrhagic) or volume (large or small) of stroke);\n4. Visible finger flexor activation\u002Fmovement\n5. The ability to give consent\n\nExclusion criteria:\n\n1. Patients with visual deficit\u002Fneglect; hearing or cognitive impairment;\n2. Patients that are currently adjusting tone alternating medications (e.g., baclofen), or\n3. Patients received botulinum toxin injection to the arm\u002Ffingers \\\u003C4 months, or phenol injections \\\u003C2 years;\n4. Patients with pacemaker, metal implants or supplemental oxygen;\n5. Patients who have musculoskeletal disorders, including pain in the affected side\n6. Women who are pregnant.","ALL","18 Years","75 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall goal is to investigate the effectiveness of a novel intervention - transcranial alternating current stimulation (tACS) for motor recovery in stroke survivors.",[27],"Motor Recovery",[29,30],"tACS","Motor recovery","RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-03","ACTUAL",{"date":37,"type":35},"2025-09-01",{"date":39,"type":21},"2028-03-31",{"name":41,"class":42},"The University of Texas Health Science Center, Houston","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100420116","breestim-for-post-stroke-motor-recovery-100420116","NCT04750551","BreEStim for Post-Stroke Motor Recovery","BreEStim for Motor Recovery in Chronic Stroke With Moderate Impairment (Pilot).","Inclusion criteria:\n\n* has post stroke ≥ 6 months , medically stable;\n* Unilateral, single stroke (no restriction on type (ischemic or hemorrhagic) or volume (large or small) of stroke);\n* MAS score ≥ 1, i.e., detectable finger flexor hypertonia;\n\nExclusion criteria include:\n\n* Patients with visual deficit\u002Fneglect; hearing or cognitive impairment;\n* Patients with history of pulmonary disease (Asthma, chronic obstruction pulmonary disease, COPD);\n* Patients that are currently adjusting tone alternating medications (e.g., baclofen), or\n* Patients received botulinum toxin injection to the arm\u002Ffingers \\\u003C4 months, or phenol injections \\\u003C 2 years;\n* Patients with a pacemaker;\n* Women who are pregnant.",{"count":52,"type":21},4,[24],"The overall goal is to investigate the effectiveness of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) on finger flexor spasticity reduction and hand function improvement in chronic stroke with moderate impairment.",[27],[57,27,58],"Finger flexor spasticity","BreEStim",{"date":34,"type":35},{"date":61,"type":35},"2025-11-01",{"date":63,"type":21},"2027-12-31",{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":48,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":78,"locationsCount":43},"100420252","breestim-for-motor-recovery-in-chronic-stroke-with-moderate-impairment-after-a-long-term-use-pilot-100420252","NCT04752319","BreEStim for Motor Recovery in Chronic Stroke With Moderate Impairment After a Long-term Use (Pilot).",{"count":52,"type":21},[24],"The overall goal is to investigate the effectiveness of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) on finger flexor spasticity reduction and hand function improvement in chronic stroke with moderate impairment after a long-term use.",[27],[57,27,58],{"date":34,"type":35},{"date":37,"type":35},{"date":39,"type":21},{"name":41,"class":42},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":48,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":92,"locationsCount":43},"100420117","breestim-for-motor-recovery-in-chronic-stroke-with-severe-impairment-pilot-100420117","NCT04750564","BreEStim for Motor Recovery in Chronic Stroke With Severe Impairment (Pilot)",{"count":52,"type":21},[24],"The overall goal is to investigate the effectiveness of a novel intervention - Breathing-controlled electrical stimulation (BreEStim) on finger flexor spasticity reduction and hand function improvement in chronic stroke with severe impairment.",[27],[57,27,58],{"date":34,"type":35},{"date":37,"type":35},{"date":63,"type":21},{"name":41,"class":42},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":115,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":147,"locationsCount":43},"100612195","development-and-efficacy-of-a-novel-cost-effective-gait-training-device-utilized-at-home-for-stroke-survivors-100612195","NCT07250425","Development and Efficacy of a Novel, Cost-Effective Gait Training Device Utilized at Home for Stroke Survivors","Development of a Novel, Cost-Effective Gait Training Device Utilized at Home for the Neurological Patient Population","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* First-ever ischemic or hemorrhagic stroke confirmed by medical record.\n* 3 months to 5 years post-stroke at time of enrollment.\n* Presence of lower-extremity motor impairment limiting walking function.\n* Able to stand for at least 30 minutes with no more than minimal assistance (with or without a device).\n* Medically stable and cleared by a physician to participate in moderate-intensity ambulation exercise.\n* Living in a home environment that can safely accommodate device installation (e.g., adequate space, appropriate flooring, and power access) as determined by the study team.\n* Able to understand study procedures and provide informed consent (or have a legally authorized representative), with sufficient cognitive and communication skills to follow simple instructions.\n* If assistance is required for transfers or device set-up, availability of a caregiver or assistant willing to participate in training and device use.\n\nExclusion Criteria:\n\n* Unstable cardiovascular, respiratory, or other medical conditions that contraindicate moderate- to high-intensity walking exercise (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmias).\n* Severe musculoskeletal or orthopedic conditions limiting safe participation in supported stepping (e.g., unstable fractures, severe contractures preventing positioning in the device).\n* Severe spasticity or movement disorders that would preclude safe use of the device, based on investigator judgment.\n* Severe cognitive impairment, aphasia, or behavioral disturbance that would prevent informed consent or safe participation.\n* Progressive neurological conditions (e.g., progressive neurodegenerative disease) expected to significantly worsen over the 12-week study period.\n* Current participation in another interventional trial targeting gait or lower-extremity function.\n* Any other condition that, in the opinion of the investigators, would make participation unsafe or interfere with study adherence or outcome interpretation.",{"count":101,"type":21},20,[24],"This pilot, parallel-group randomized controlled trial will evaluate the feasibility, safety, usability, and preliminary efficacy of the Rise\\&Walk InHome (RWH), a novel robotic gait training device designed for home use after stroke. Twenty adults with lower-extremity motor impairment following a first-ever stroke (3 months to 5 years post-event) will be randomized 1:1 to either (1) RWH-assisted home walking plus usual care or (2) usual care alone for 12 weeks. Participants in the intervention group will receive an in-home RWH device, complete a structured device training program, and be instructed to perform 30-minute RWH walking sessions four times per week (48 sessions total). All participants will undergo standardized outcome assessments at baseline, weeks 4, 8, and 12, including the 6-Minute Walk Test (primary outcome), 10-Meter Walk Test, daily step count via wearable activity tracker, and health-related quality of life (SF-36). Additional feasibility and usability outcomes include device use and adherence, patient satisfaction and motivation, ease of use, perceived exertion, and adverse events. Findings will inform the feasibility of in-home deployment of the RWH device and provide preliminary effect-size estimates to guide the design of a larger efficacy trial.",[105,106,107,108,109,27,110,111,112,113,114],"Stroke","Neurological Diseases or Conditions","Hemiparesis;Poststroke\u002FCVA","Gait Disorders, Neurologic","Post Stroke Fatigue","Walking Difficulty","Balance Impairment","Falls Prevention","Hemiparesis","Mobility Limitation",[116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139],"in-home rehabilitation","Robotic-Assisted Gait Training","gait training device","stroke recovery","functional mobility","rehabilitation technology","remote monitoring","rehabilitation robotics","Fitbit Step Tracking","Self-Directed Gait Training","high-intensity gait training","Neurorehabilitation Research","Lower Limb Rehabilitation","Motor Function Recovery","Physical Therapy","Walking Endurance","task specific walking practice","neurological recovery","stroke rehabilitation","home exercise program","Rise&Walk InHome","daily step count","6-minute walk test","10-meter walk test","NOT_YET_RECRUITING","2026-03-06",{"date":143,"type":35},"2026-03-09",{"date":145,"type":21},"2026-08",{"date":145,"type":21},{"name":148,"class":42},"Healing Innovations",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":43},"100525454","safety-and-efficacy-study-of-implantable-neuromodulation-for-poststroke-hemiplegia-100525454","NCT06121947","Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia","Comparative Study of the Efficacy and Safety of Deep Brain Stimulation Versus Vagal Stimulation for Post-stroke Hemiplegia: Study Protocol for a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meet WHO or international diagnostic criteria for stroke disease;\n2. The first unilateral supratentorial ischemic or hemorrhagic stroke, the condition is stable after acute treatment of ischemic stroke, the course of disease is 6 months ≤ 1 year, and participate in 2 evaluations (screening and baseline) before enrollment.\n3. Diagnosed by professional physicians combined with brain CT or magnetic resonance imaging and other imaging techniques;\n4. Between the ages of 18 and 80, male or female\n5. The responsible lesion in the unilateral white matter area indicated by cranial CT or MRI\n6. Relevant sequelae such as limb dysfunction after stroke, accompanied by unilateral limb motor dysfunction, proved to be right-handed by standardized examination.\n7. National Institutes of Health Stroke Scale (NIHSS) score from 2 to 20, grades paralyzed muscle strength, between grades 1 and 4, WISCI II, grade \\>2 (0-20 items): Assisted by one or more persons, able to walk at least 10 m, and less responsive to conventional rehabilitation prior to inclusion.\n8. Perfect clinical data\n9. Stable medical and physical condition with adequate nursing support and appropriate medical care in the patient's home community.\n10. The patient himself or voluntarily signs the informed consent and is willing to cooperate with relevant treatmen\n\nExclusion Criteria:\n\n1. Glasgow Coma Scale (GSC) score below 15, Minimum Mental State Examination (MMSE) assessment for dementia indicated, suffering from mental disturbance and unable to cooperate with examination or treatment.\n2. Motor and sensory disturbances are not induced by stroke, nor by previous ischemic stroke, but stroke induced by trauma, brain tumor, etc.\n3. Serious comorbidities, such as malignant tumors, primary heart, liver, kidney or hematopoietic system diseases.\n4. History of cognitive impairment, mental disorder, drug abuse, drug allergy, and alcoholism.\n5. Infection or rupture of the skin on the forearm or leg.\n6. Possess a pacemaker, metal stent, plate, or implant susceptible to electrical impulses in the body (pacemaker or defibrillator, baclofen pump, deep brain stimulator, Ventricular shunts, shrapnel, etc.).\n7. Pregnant or breast-feeding or have a recent birth plan.\n8. IS CLASSROUS.\n9. Congenital or acquired abnormalities of lower extremities (affecting joints and bones).\n10. Registration of investigators, their family members, employees, and other dependents.\n11. Severe joint contractures cause loss or limitation of lower limb activities.\n12. Blood system diseases with increased risk of bleeding during surgical intervention.\n13. Participate in another study drug study within 30 days before and during this study.\n14. Unable to complete the basic process, or difficult to maintain compliance and follow-up","80 Years",{"count":158,"type":21},98,[24],"Background: Hemiplegia is a common complication after a stroke. Studies have shown that traditional medical and rehabilitation treatments are not good for improving patients' motor function, deep brain stimulation (DBS) and vagus nerve stimulation (VNS) can improve the motor function of patients, but there is no comparative study between them. Objectives: This study compares the efficacy and safety of DBS and VNS in the recovery of motor function in patients with post-stroke hemiplegia, determining the best treatment for patients with post-stroke hemiplegia, and providing high-level clinical evidence for patients and clinicians to choose from. Methods\u002FDesign: This is a randomized, double-blind, sham-controlled, cross-controlled pilot study. A total of 98 patients with post-stroke hemiplegia are assigned to receive DBS or VNS. After 3 and 6 months of follow-up, all the devices are turned off. After a 2-week washout, the control group is turned on, but the stimulation group is given sham stimulation. After 9 and 12 months of follow-up, all the devices are turned on. Then, at postoperative 15 and 18 months, postoperative neuroimaging and various post-stroke motor-related scores were performed for data collection and analysis. Discussion: We propose a study design and rationale to compare the efficacy and safety of DBS and VNS in patients with post-stroke hemiplegia to provide evidence and reference for implantable neuromodulation in the treatment of post-stroke dysfunction, and to compare the therapeutic effects of DBS and VNS to provide evidence for patient and clinical diagnosis and treatment choices. Study limitations are related to the small sample size and short study period.",[162,163,164,27,105,165],"Stroke Sequelae","Deep Brain Stimulation","Vagus Nerve Stimulation","Hemiplegia","2023-11-02",{"date":168,"type":35},"2023-11-08",{"date":170,"type":21},"2023-11-10",{"date":172,"type":21},"2030-10-30",{"name":174,"class":42},"Chinese PLA General Hospital"]